Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review
Restricted accessReview articleFirst published online May, 2020
Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review
We present two patients with recurrent, metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-based chemotherapy and radiotherapy (RT) with complete response via abscopal effect following combined immunotherapy (IT) and stereotactic body radiation therapy (SBRT). We review the literature for patients undergoing combined treatment with IT and RT to identify potential cases of abscopal response.
Study Design:
This is a case series with a contemporary review of the literature.
Methods:
Retrospective chart review identified two patients with potential abscopal responses after IT and RT for R/M HNSCC. The MEDLINE database was queried using the search terms “abscopal AND head and neck squamous cell carcinoma” and “immunotherapy AND stereotactic body radiation therapy.”
Results:
Two patients with metastatic HNSCC developed complete responses via a possible abscopal effect following combined SBRT and IT. Interim follow-up of both patients revealed a sustained, complete response. We examine the immunogenic effects of RT and report the first cases of potential abscopal effect for R/M HNSCC. We also review several preclinical studies demonstrating the synergistic efficacy of combined RT and IT with a discussion of possible mechanism.
Conclusion:
Observation of abscopal effect with combined IT and RT is currently under investigation through several preclinical studies and trials. To the best of our knowledge, these are the first two reported cases of abscopal effect for patients with HNSCC. We report two patients with R/M HNSCC with sustained, complete response after systemic IT and local RT.
MouldRF. Invited review: the early years of radiotherapy with emphasis on X-ray and radium apparatus. Br J Radiol. 1995;68(810):567-582.
2.
LeeYAuhSLWangY, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589-595.
3.
ZouWChenL. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467-477.
4.
MoleRH. Whole body irradiation—radiobiology or medicine?Br J Radiol. 1953;26(305):234-241.
5.
VeselyMDKershawMHSchreiberRDSmythMJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-271.
6.
KollerKMMackleyHBLiuJ, et al. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther. 2017;18(1):36-42.
7.
GrimaldiAMSimeoneEGiannarelliD, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3:e28780.
8.
AboudaramAModestoAChaltielL, et al. Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination. Melanoma Res. 2017;27(5):485-491.
9.
VatnerRECooperBTVanpouille-BoxCDemariaSFormentiSC. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol. 2014;4:325.
10.
DemariaSBhardwajNMcbrideWHFormentiSC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005;63(3):655-666.
11.
VereecqueRBuffenoirGGonzalezR, et al. Gamma-ray irradiation induces B7.1 expression in myeloid leukaemic cells. Br J Haematol. 2000;108(4):825-831.
12.
VondracekJSheardMAKrejciPMinksovaKHofmanovaJKozubikA. Modulation of death receptor-mediated apoptosis in differentiating human myeloid leukemia HL-60 cells. J Leukoc Biol. 2001;69(5):794-802.
13.
ChakrabortyMAbramsSICamphausenK, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 2003;170(12):6338-6347.
14.
ReitsEAHodgeJWHerbertsCA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259-1271.
15.
LiuYDongYKongLShiFZhuHYuJ. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):104.
16.
FormentiSCDemariaS. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10(7):718-726.
17.
RosenEMFanSRockwellSGoldbergID. The molecular and cellular basis of radiosensitivity: implications for understanding how normal tissues and tumors respond to therapeutic radiation. Cancer Invest. 1999;17(1):56-72.
18.
PikeLRGBangAMahalBA, et al. The impact of radiation therapy on lymphocyte count and survival in metastatic cancer patients receiving PD-1 immune checkpoint inhibitors. Int J Radiat Oncol Phys. 2019;103(1):142-151.
19.
KoECBenjaminKTFormentiSC. Generating antitumor immunity by targeted radiation therapy: role of dose and fractionation. Adv Radiat Oncol. 2018;3(4):486-493.
20.
GargADKryskoDVVerfaillieT, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012;31(5):1062-1079.
21.
GardaiSJMcPhillipsKAFraschSC, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123(2):321-334.
22.
PanaretakisTKeppOBrockmeierU, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009;28(5):578-590.
23.
ChekeniFBElliottMRSandilosJK, et al. Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis. Nature. 2010;467(7317):863-867.
24.
GanssRRyschichEKlarEArnoldBHammerlingGJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002;62(5):1462-1470.
25.
HallahanDKuchibhotlaJWybleC. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res. 1996; 56(22):5150-5155.
26.
MatsumuraSWangBKawashimaN, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;181(5):3099-3107.
27.
AzourySCStraughanDMShuklaV. Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets. 2015;15(6):452-462.
28.
MahoneyKMRennertPDFreemanGJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561-584.
29.
PennockGKChowLQM. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015;20(7):812-822.
30.
HodiFSO’DaySJMcDermottDF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
31.
SilkAWBassettiMFWestBTTsienCILaoCD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2013;2(6):899-906.
32.
TaubeJMAndersRAYoungGD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.
33.
LatchmanYWoodCRChernovaT, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261-268.
34.
FranciscoLMSalinasVHBrownKE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015-3029.
35.
FliesDBChenL. The new B7s: playing a pivotal role in tumor immunity. J Immunother. 2007;30(3):251-260.
36.
LarkinsEBlumenthalGMYuanW, et al. FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist. 2017;22(7):873-878.
37.
ZengJSeeAPPhallenJ, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343-349.
38.
DengLLiangHBurnetteB, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687-695.
39.
ParkSSDongHLiuX, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3(6):610-619.
40.
Rodriguez-RuizMERodriguezIGarasaS, et al. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming. Cancer Res. 2016;76(20):5994-6005.
41.
GoldenEBChhabraAChachouaA, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795-803.
42.
TheelenWSMEPeulenHMULalezariF, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial [published online July 11, 2019]. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.1478
43.
KiessAPWolchokJDBarkerCA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92(2):368-375.
44.
MorisadaMChamberlinMAllenC. Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer. Head Neck. 2018;40(6):1321-1334.
